Reuters: AstraZeneca COVID-19 vaccine trial Brazil volunteer dies, trial to continue
“Brazilian health authority Anvisa said on Wednesday that a volunteer in a clinical trial of the COVID-19 vaccine developed by AstraZeneca and Oxford University had died but added that the trial would continue. … A source familiar with the matter told Reuters the trial would have been suspended if the volunteer who died had received the COVID-19 vaccine, suggesting the person was part of the control group that was given a meningitis jab…” (Simoes, 10/21).

Washington Post: Unprecedented vaccine trials on track to begin delivering results
“In a matter of weeks, one of the most closely watched human experiments in history will start to report early results, with data on prospective coronavirus vaccines possibly coming this month or in November from the pharmaceutical giant Pfizer and the biotechnology company Moderna. Amid the turmoil, chaos, and misinformation that have defined the U.S. response to the pandemic, progress toward a vaccine, or vaccines, has been steady, reassuring, and scientific…” (Johnson, 10/21).

AP: Brazil’s Bolsonaro rejects coronavirus vaccine from China (Savarese, 10/21).

Bloomberg: Deceased AstraZeneca Trial Volunteer Didn’t Receive Vaccine (Annett/Brandimarte, 10/21).

Financial Times: How much will a Covid-19 vaccine cost? (Peel et al., 10/22).

The Hill: COVID-19 vaccine trial will continue after subject given placebo dies in Brazil (Budryk, 10/21).

POLITICO: AstraZeneca close to restarting Covid-19 vaccine trial in U.S. (Brennan, 10/21).

Roll Call: COVID-19 trials risk excluding those most vulnerable to virus (Siddons, 10/22).

TIME: You Can Now Get a COVID-19 Vaccine in China. That Might Not Be a Good Thing (Campbell, 10/22).

Wall Street Journal: How Pfizer Partner BioNTech Became a Leader in Coronavirus Vaccine Race (Pancevski/Hopkins, 10/22).